Top

Published in:

01-03-2009

Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii

Authors: Jeffrey G. Shannon, Robert A. Heinzen

Published in: Immunologic Research | Issue 1-3/2009

Abstract

Coxiella burnetii is an obligate intracellular bacterial pathogen that causes the zoonosis Q fever. While an effective whole-cell vaccine (WCV) against Q fever exists, the vaccine has limitations in being highly reactogenic in sensitized individuals. Thus, a safe and effective vaccine based on recombinant protein antigen (Ag) is desirable. To achieve this goal, a better understanding of the host response to primary infection and the precise mechanisms involved in protective immunity to C. burnetii are needed. This review summarizes our current understanding of adaptive immunity to C. burnetii with a focus on recent developments in the field.

Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12(4):518–53.PubMed

Comer JA, Paddock CD, Childs JE. Urban zoonoses caused by Bartonella, Coxiella, Ehrlichia, and Rickettsia species. Vector Borne Zoonotic Dis. 2001;1(2):91–118.PubMedCrossRef

Marmion BP, Ormsbee RA, Kyrkou M, Wright J, Worswick DA, Izzo AA, et al. Vaccine prophylaxis of abattoir-associated Q fever: eight years’ experience in Australian abattoirs. Epidemiol Infect. 1990;104(2):275–87.PubMed

Voth DE, Heinzen RA. Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetii. Cell Microbiol. 2007;9(4):829–40.PubMedCrossRef

Sauer JD, Shannon JG, Howe D, Hayes SF, Swanson MS, Heinzen RA. Specificity of Legionella pneumophila and Coxiella burnetii vacuoles and versatility of Legionella pneumophila revealed by coinfection. Infect Immun. 2005;73(8):4494–504.PubMedCrossRef

Hackstadt T, Williams JC. Biochemical stratagem for obligate parasitism of eukaryotic cells by Coxiella burnetii. Proc Natl Acad Sci U S A. 1981;78(5):3240–4.PubMedCrossRef

Capo C, Lindberg FP, Meconi S, Zaffran Y, Tardei G, Brown EJ, et al. Subversion of monocyte functions by Coxiella burnetii: impairment of the cross-talk between alphaVbeta3 integrin and CR3. J Immunol. 1999;163(11):6078–85.PubMed

Ghigo E, Capo C, Tung CH, Raoult D, Gorvel JP, Mege JL. Coxiella burnetii survival in THP-1 monocytes involves the impairment of phagosome maturation: IFN-gamma mediates its restoration and bacterial killing. J Immunol. 2002;169(8):4488–95.PubMed

Hackstadt T. Antigenic variation in the phase I lipopolysaccharide of Coxiella burnetii isolates. Infect Immun. 1986;52(1):337–40.PubMed

10.

Hackstadt T, Peacock MG, Hitchcock PJ, Cole RL. Lipopolysaccharide variation in Coxiella burnettii: intrastrain heterogeneity in structure and antigenicity. Infect Immun. 1985;48(2):359–65.PubMed

11.

Moos A, Hackstadt T. Comparative virulence of intra- and interstrain lipopolysaccharide variants of Coxiella burnetii in the guinea pig model. Infect Immun. 1987;55(5):1144–50.PubMed

12.

Vishwanath S, Hackstadt T. Lipopolysaccharide phase variation determines the complement-mediated serum susceptibility of Coxiella burnetii. Infect Immun. 1988;56(1):40–4.PubMed

13.

Zamboni DS, Campos MA, Torrecilhas AC, Kiss K, Samuel JE, Golenbock DT, et al. Stimulation of toll-like receptor 2 by Coxiella burnetii is required for macrophage production of pro-inflammatory cytokines and resistance to infection. J Biol Chem. 2004;279(52):54405–15.

14.

Honstettre A, Ghigo E, Moynault A, Capo C, Toman R, Akira S, et al. Lipopolysaccharide from Coxiella burnetii is involved in bacterial phagocytosis, filamentous actin reorganization, and inflammatory responses through toll-like receptor 4. J Immunol. 2004;172(6):3695–703.PubMed

15.

Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419–26.PubMedCrossRef

16.

Shannon JG, Howe D, Heinzen RA. Virulent Coxiella burnetii does not activate human dendritic cells: role of lipopolysaccharide as a shielding molecule. Proc Natl Acad Sci U S A. 2005;102(24):8722–7.PubMedCrossRef

17.

Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A. 2002;99(1):351–8.PubMedCrossRef

18.

Verhasselt V, Vosters O, Beuneu C, Nicaise C, Stordeur P, Goldman M. Induction of FoxP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells. Eur J Immunol. 2004;34(3):762–72.PubMedCrossRef

19.

Neild AL, Roy CR. Immunity to vacuolar pathogens: what can we learn from Legionella? Cell Microbiol. 2004;6(11):1011–8.PubMedCrossRef

20.

Pamer EG. Immune responses to Listeria monocytogenes. Nat Rev Immunol. 2004;4(10):812–23.PubMedCrossRef

21.

Reece ST, Kaufmann SH. Rational design of vaccines against tuberculosis directed by basic immunology. Int J Med Microbiol. 2008;298(1–2):143–50.PubMedCrossRef

22.

Izzo AA, Marmion BP, Hackstadt T. Analysis of the cells involved in the lymphoproliferative response to Coxiella burnetii antigens. Clin Exp Immunol. 1991;85(1):98–108.PubMedCrossRef

23.

Izzo AA, Marmion BP, Worswick DA. Markers of cell-mediated immunity after vaccination with an inactivated, whole-cell Q fever vaccine. J Infect Dis. 1988;157(4):781–9.PubMed

24.

Hinrichs DJ, Jerrells TR. In vitro evaluation of immunity to Coxiella burnetii. J Immunol. 1976;117(3):996–1003.PubMed

25.

Brennan RE, Russell K, Zhang G, Samuel JE. Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections. Infect Immun. 2004;72(11):6666–75.PubMedCrossRef

26.

Turco J, Thompson HA, Winkler HH. Interferon-gamma inhibits growth of Coxiella burnetii in mouse fibroblasts. Infect Immun. 1984;45(3):781–3.PubMed

27.

Howe D, Barrows LF, Lindstrom NM, Heinzen RA. Nitric oxide inhibits Coxiella burnetii replication and parasitophorous vacuole maturation. Infect Immun. 2002;70(9):5140–7.PubMedCrossRef

28.

Raoult D, Marrie T, Mege J. Natural history and pathophysiology of Q fever. Lancet Infect Dis. 2005;5(4):219–26.PubMedCrossRef

29.

Andoh M, Zhang G, Russell-Lodrigue KE, Shive HR, Weeks BR, Samuel JE. T cells are essential for bacterial clearance, and gamma interferon, tumor necrosis factor alpha, and B cells are crucial for disease development in Coxiella burnetii infection in mice. Infect Immun. 2007;75(7):3245–55.PubMedCrossRef

30.

Sidwell RW, Gebhardt LP. Studies of latent Q fever infections. 3. Effects of parturition upon latently infected guinea pigs and white mice. Am J Epidemiol. 1966;84(1):132–7.PubMed

31.

Sidwell RW, Thorpe BD, Gebhardt LP. Studies on latent Q fever infections I. Effects of whole body x-irradiation upon latently infected guinea pigs, white mice and deer mice. Am J Hyg. 1964;79:113–24.PubMed

32.

Sidwell RW, Thorpe BD, Gebhardt LP. Studies of latent Q fever infections. II. Effects of multiple cortisone injections. Am J Hyg. 1964;79:320–7.PubMed

33.

Zhang G, Russell-Lodrigue KE, Andoh M, Zhang Y, Hendrix LR, Samuel JE. Mechanisms of vaccine-induced protective immunity against Coxiella burnetii infection in balb/c mice. J Immunol. 2007;179(12):8372–80.PubMed

34.

Casadevall A, Pirofski LA. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol. 2006;91:1–44.PubMedCrossRef

35.

Fournier PE, Marrie TJ, Raoult D. Diagnosis of Q fever. J Clin Microbiol. 1998;36(7):1823–34.PubMed

36.

Burnet FM, Freeman M. “Q” fever: factors affecting the appearance of Rickettsiae in mice. Med J Aust. 1938;2:1114–6.

37.

Burnet FM, Freeman M. Studies on the x strain (dyer) of Rickettsia burneti. II. Guinea pig infections with special reference to immunological phenomena. J Immunol. 1941;40:421–36.

38.

Kazar J, Skultetyova E, Brezina R. Phagocytosis of Coxiella burneti by macrophages. Acta Virol. 1975;19(5):426–31.PubMed

39.

Humphres RC, Hinrichs DJ. Role of antibody in Coxiella burnetii infection. Infect Immun. 1981;31(2):641–5.PubMed

40.

Williams JC, Peacock MG, Waag DM, Kent G, England MJ, Nelson G, et al. Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetii for the immunization of animals. Ann N Y Acad Sci. 1992;653:88–111.PubMedCrossRef

41.

Brooks DL, Ermel RW, Franti CE, Ruppanner R, Behymer DE, Williams JC, et al. Q fever vaccination of sheep: challenge of immunity in ewes. Am J Vet Res. 1986;47(6):1235–8.PubMed

42.

Waag DM, England MJ, Bolt CR, Williams JC. Phase 1 clinical trial of CMR Q fever vaccine: low-dose priming enhances humoral and cellular immune responses to Coxiella burnetii. Clin Vaccine Immunol. 2008 [Epub ahead of print].

43.

Genig VA. A live vaccine 1-M-44 against Q-fever for oral use. J Hyg Epidemiol Microbiol Immunol. 1968;12(3):265–73.PubMed

44.

Johnson JW, McLeod CG, Stookey JL, Higbee GA, Pedersen CE Jr. Lesions in guinea pigs infected with Coxiella burnetii strain M-44. J Infect Dis. 1977;135(6):995–8.PubMed

45.

Ormsbee RA, Bell EJ, Lackman DB, Tallent G. The influence of phase on the protective potency of Q fever vaccine. J Immunol. 1964;92:404–12.PubMed

46.

Abinanti FR, Marmion BP. Protective or neutralizing antibody in Q fever. Am J Hyg. 1957;66(2):173–95.PubMed

47.

Behymer DE, Biberstein EL, Riemann HP, Franti CE, Sawyer M, Ruppanner R, et al. Q fever (Coxiella burnetii) investigations in dairy cattle: challenge of immunity after vaccination. Am J Vet Res. 1976;37(6):631–4.PubMed

48.

Biberstein EL, Riemann HP, Franti CE, Behymer DE, Ruppanner R, Bushnell R, et al. Vaccination of dairy cattle against Q fever (Coxiella burneti): results of field trials. Am J Vet Res. 1977;38(2):189–93.PubMed

49.

Waag DM, Kende M, Damrow TA, Wood OL, Williams JC. Injection of inactivated phase I Coxiella burnetii increases non-specific resistance to infection and stimulates lymphokine production in mice. Ann N Y Acad Sci. 1990;590:203–14.PubMedCrossRef

50.

Marmion BP, Ormsbee RA, Kyrkou M, Wright J, Worswick D, Cameron S, et al. Vaccine prophylaxis of abattoir-associated Q fever. Lancet. 1984;2(8417–8):1411–4.PubMedCrossRef

51.

Ackland JR, Worswick DA, Marmion BP. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-vax (CSL) 1985–1990. Med J Aust. 1994;160(11):704–8.PubMed

52.

Zhang YX, Zhi N, Yu SR, Li QJ, Yu GQ, Zhang X. Protective immunity induced by 67 k outer membrane protein of phase I Coxiella burnetii in mice and guinea pigs. Acta Virol. 1994;38(6):327–32.PubMed

53.

Williams JC, Hoover TA, Waag DM, Banerjee-Bhatnagar N, Bolt CR, Scott GH. Antigenic structure of Coxiella burnetii. A comparison of lipopolysaccharide and protein antigens as vaccines against Q fever. Ann N Y Acad Sci. 1990;590:370–80.PubMedCrossRef

54.

Zhang GQ, Samuel JE. Identification and cloning potentially protective antigens of Coxiella burnetii using sera from mice experimentally infected with Nine Mile phase I. Ann N Y Acad Sci. 2003;990:510–20.PubMedCrossRef

55.

Li Q, Niu D, Wen B, Chen M, Qiu L, Zhang J. Protective immunity against Q fever induced with a recombinant P1 antigen fused with HspB of Coxiella burnetii. Ann N Y Acad Sci. 2005;1063:130–42.PubMedCrossRef

56.

Boschini A, Di Perri G, Legnani D, Fabbri P, Ballarini P, Zucconi R, et al. Consecutive epidemics of Q fever in a residential facility for drug abusers: impact on persons with human immunodeficiency virus infection. Clin Infect Dis. 1999;28(4):866–72.PubMedCrossRef

57.

Fenollar F, Fournier PE, Carrieri MP, Habib G, Messana T, Raoult D. Risks factors and prevention of Q fever endocarditis. Clin Infect Dis. 2001;33(3):312–6.PubMedCrossRef

58.

Brouqui P, Raoult D. New insight into the diagnosis of fastidious bacterial endocarditis. FEMS Immunol Med Microbiol. 2006;47(1):1–13.PubMedCrossRef

59.

Capo C, Zaffran Y, Zugun F, Houpikian P, Raoult D, Mege JL. Production of interleukin-10 and transforming growth factor beta by peripheral blood mononuclear cells in Q fever endocarditis. Infect Immun. 1996;64(10):4143–7.PubMed

60.

Honstettre A, Imbert G, Ghigo E, Gouriet F, Capo C, Raoult D, et al. Dysregulation of cytokines in acute Q fever: role of interleukin-10 and tumor necrosis factor in chronic evolution of Q fever. J Infect Dis. 2003;187(6):956–62.PubMedCrossRef

61.

Aliberti J. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat Rev Immunol. 2005;5(2):162–70.PubMedCrossRef

62.

Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007;28(9):378–84.PubMedCrossRef

63.

Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003;3(9):578–90.PubMedCrossRef

64.

Ghigo E, Capo C, Raoult D, Mege JL. Interleukin-10 stimulates Coxiella burnetii replication in human monocytes through tumor necrosis factor down-modulation: role in microbicidal defect of Q fever. Infect Immun. 2001;69(4):2345–52.PubMedCrossRef

65.

Meghari S, Bechah Y, Capo C, Lepidi H, Raoult D, Murray PJ, et al. Persistent Coxiella burnetii infection in mice overexpressing IL-10: an efficient model for chronic Q fever pathogenesis. PLoS Pathog. 2008;4(2):e23.PubMedCrossRef

66.

Suvas S, Rouse BT. Treg control of antimicrobial T cell responses. Curr Opin Immunol. 2006;18(3):344–8.PubMedCrossRef

67.

Koster FT, Williams JC, Goodwin JS. Cellular immunity in Q fever: modulation of responsiveness by a suppressor T cell-monocyte circuit. J Immunol. 1985;135(2):1067–72.PubMed

68.

Koster FT, Williams JC, Goodwin JS. Cellular immunity in Q fever: specific lymphocyte unresponsiveness in Q fever endocarditis. J Infect Dis. 1985;152(6):1283–9.PubMed

Title: Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii
Authors: Jeffrey G. Shannon
Robert A. Heinzen
Publication date: 01-03-2009
Publisher: Humana Press Inc
Published in: Immunologic Research / Issue 1-3/2009
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-008-8059-4

At a glance: The STEP trials

Springer Medicine

Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-3/2009

Understanding B cell activation: from single molecule tracking, through Tolls, to stalking memory in malaria

The technological transformation of patient-driven human immunology research

Innate immunity in the pathogenesis of polytropic retrovirus infection in the central nervous system

Activation and regulation of Toll-Like Receptors (TLRs) by helminth parasites

Innate immune recognition of nucleic acids

Differential roles for the inositol phosphatase SHIP in the regulation of macrophages and lymphocytes